Monoclonal antibodies

Novartis head office
#Anthos Therapeutics #Cardiovascular disease #Mergers and acquisitions #Monoclonal antibodies #Novartis

Novartis acquires Anthos Therapeutics for $925 million

Novartis has agreed to acquire Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathway.  Abelacimab is currently in Phase III development, with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillation.  Novartis will make an… Read More

#Business & Investment #News #Trending News

Mosquito
#Immunology / Virology & Vaccines #Monoclonal antibodies #National Institutes of Health (NIH) #Phase II trial

Phase II trial will test monoclonal antibody for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment for the effects of dengue, a mosquito-borne viral disease.   The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).  It will test the ability of… Read More

#News

#Financing #Helicore Biopharma #Monoclonal antibodies #Obesity #Weight loss

Obesity drug developer emerges from stealth with a $65m financing

Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions.  Helicore’s most advanced asset,… Read More

#Business & Investment #News

The European Medicines Agency in Amsterdam
#European Commission #Monoclonal antibodies #Myeloma #Oncology #Sanofi

EU extends Sarclisa use to newly diagnosed multiple myeloma

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has now approved Sanofi’s monoclonal antibody Sarclisa (isatuximab).  It is approved in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult… Read More

#News #Regulatory

Business financing
#Asthma #Financing #Immunology #Monoclonal antibodies #Windward Bio

Windward Bio launches with $200 million

Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal… Read More

#Business & Investment #News #Start-up Zone

Tau proteins
#Alzheimer's #Fast Track designation #FDA #Johnson & Johnson #Monoclonal antibodies #Neuroscience

Tau-directed mAb receives US FDA fast track designation

The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).  The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.   It has shown potential in targeting disease-associated… Read More

#News #Regulatory

Mosquito
#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies #National Institutes of Health (NIH)

Researchers discover novel class of anti-malaria antibodies

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science.   Of the five species of… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#BioArctic #Monoclonal antibodies #Neuroscience #Parkinson's #Phase II trial

Clinical trial will test monoclonal antibody in Parkinson’s disease

BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients.   Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders… Read More

#News

Monoclonal antibodies
#Ark Biopharmaceutical #Monoclonal antibodies #Phase I trial #Respiratory syncytial virus #Virology

Potential monoclonal antibody to prevent RSV enters human trials

Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection.  The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible… Read More

#News

#Antibody #Antibody libraries #Drug development #Drug discovery #Monoclonal antibodies

A pioneering approach to biotherapeutic antibody discovery 

This is a paid-for advertorial by BIO-RAD. Immunotherapy has revolutionised cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen. … Read More

#Exclusive Content

EMA
#European Medicines Agency #Monoclonal antibodies #Paediatrics #Phase III trial #Regeneron Pharmaceuticals #Sanofi

EU Dupixent use extended to children with eosinophilic esophagitis

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates… Read More

#News #Regulatory

Human liver
#Cardiometabolic diseases #GLP-1 #Monoclonal antibodies #Obesity #Tiziana Life Sciences

Ozempic and antibody combination restores liver homeostasis

New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy). The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO). Read More

#News

Antibodies
#Immunotherapy #Interview #Monoclonal antibodies #Oncology #Therapeutic Antibodies

The new wave: Creating next-gen antibody therapies

Diana Spencer speaks to Dr Wansu Qiu, Technical Account Manager at Sino Biological US, about how advances in engineering technologies are paving the way for improved antibody drugs. DS: Since 1986, the FDA has granted marketing authorisation to over 100 therapeutic antibodies, many in oncology. Why has this been a… Read More

#Exclusive Content #Opinion

Non-small cell lung cancer
#Lung cancer #Monoclonal antibodies #Oncology #Phase I trial #Pierre Fabre

Trial assesses new approach to NSCLC with MET alterations

The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations. PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET. MET, also known as hepatocyte growth factor receptor… Read More

#Cancer Research #News

Monoclonal antibody
#Cancer Research UK #Clinical trial #Monoclonal antibodies #Oncology #UCB

Monoclonal antibody targets HLA-G in advanced cancers

A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers. The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The… Read More

#Cancer Research #News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News